JCARR
JOURNAL OF CLINICAL ADVANCES AND RESEARCH REVIEWS

Available online on http://www.jcarr.in/
Journal of Clinical Advances and Research Reviews 2024; 01(02); 30-40
ISSN: 3048-6556

Review

Precision Medicine and Targeted Therapies in Oncology: Advancements in Drug Discovery and Clinical Applications

Namrata Bhutani[1], Bhavit Bansal[2], Soumik Chatterjee[3], Evana Raj[4], Asutosh Pradhan*[5]

[1]*Assistant professor, Department of Biochemistry, Dr SS Tantia Medical College, Hospital & Research Centre, Sriganganagar, Rajasthan, India, 335002*

[2]*SRF, Central Council for Research in Yoga and Naturopathy*

[3]*Post Graduate Resident, KPC Medical College & Hospital, Jadavpur, Kolkata 700032*

[4]*Assistant Professor, Indore institute of Pharmacy/ Rau-Pithampur Road Opposite IIM Rau Indore, Pin code 453331*

[5]*PG 3rd Year, Dept. of OMFS, Hi Tech Dental College and Hospital, Bhubaneswar Odisha 751015*

Received: 22-06-2024 / Revised: 23-07-2024 / Accepted: 15-08-2024
Corresponding Author: Asutosh Pradhan
Email: infodrprasad@gmail.com
Conflict of interest: Nil

Abstract:

Aim: Evaluation of the frequency of different cancer kinds, evaluation of patient responses to targeted treatments, analysis of treatment-related side events, and investigation of the influence of insurance coverage on access to these medicines are the objectives of this research.

Purpose: The goal is to comprehend patient side effects, the efficacy of targeted medicines, and the function of insurance in facilitating treatment access. The purpose of this study is to provide insights that help improve patient outcomes and therapy for cancer. **Method:** A descriptive cross-sectional technique was used to assess 200 cancer patients who were undergoing targeted treatment. Standardized questionnaires were used to gather information on the different types of cancer, treatment outcomes, side effects, insurance coverage status, and demographics. **Result:** Key data showed that the most common cancer was lung cancer (20%), which was followed by colorectal cancer (15%) and breast cancer (17.5%). In response to treatment, 15% had a full response, 30% had a partial response, 35% stayed stable, and 20% saw their condition advance. Fever (20%), nausea (25%), and hair loss (15%) were among the adverse effects. In terms of insurance, 10% were uninsured, 40% had limited coverage, and 50% had complete coverage. **Conclusion:** The research emphasizes the significance of insurance coverage, the variety of therapy responses, and the intricacies of cancer treatment in precision medicine. To enhance therapeutic approaches and provide better access to vital therapies, which will ultimately improve patient care overall, more research is required.

Keywords: Cancer types, targeted treatment, patient outcomes, treatment side effects, insurance coverage, access to treatment, lung cancer, breast cancer, colorectal cancer, treatment response.

1. INTRODUCTION

There have been tremendous changes in the medical sector concerning oncology, that is the study, diagnosis, and treatment of cancer, over the years. Even though the discovery of immunotherapy, targeted treatments, and chemotherapy has led to more than doubling the treatment options, the industry is still replete with challenges [1]. One such challenge is what is known as cancer stem cells (CSCs), which regularly escape conventional treatments and stimulate the recurrence of cancer [2]. The use of resistance mechanisms mediated by proteins known as ATP-Binding Cassette (ABC) transporters by these CSCs complicates the situation even further. The complexity of the treatment outcome is further compounded by the adaptability of cancer cells and their complex interactions with the surrounding microenvironments. Furthermore, in many cancers, such as pancreatic, prostate, and esophageal types, there exists no early sign that would prompt time-bound management [3]. Due to a lack of trusted biomarkers, there can be no monitoring of the effectiveness of the therapy; thus, their capacity cannot be known early in life, meaning that interdisciplinary methods must ensure effective care.

In this demanding environment, precision medicine is revealed to be a cutting-edge response. It, therefore, tailors medical interventions to each patient's unique genetic makeup, lifestyle choices, and environmental conditions in a quest to achieve best outcomes [4]. Precision medicine is a game-changing step forward for cancer, providing focused responses to many long-standing problems such as CSCs and treatment resistance [5]. Precision medicine aims at maximizing effectiveness while minimizing adverse impacts through tailoring therapies to the specific genetic and molecular profiles of each cancer. This customization is very useful in trying to understand the complexities of the interactions of the tumor cells with the microenvironment and brings about better outcomes in therapy [6]. This will also revolutionize diagnostics especially in cancers, which mostly take place when diseases have already reached advance stages. Targeted biomarkers will help in making early identification and much more complete assessment of therapy efficacy. Precision medicine is a significant tool, not only in the treatment of cancer, but considering as well how this disease tends to branch out and consequently needs to be fought with a multi-target approach.

1.1.Advancements in Drug Discovery

Breakthroughs in precision medicine have also revolutionized the study of the field of new drugs in cancer drug development [7]. It seeks more appropriate and personalized therapy options through the identification and targeting of specific genetic alterations in cancer cells. By concentrating on specific patient attributes, scientists can design therapies that maximize benefits with minimal side effects. This integration of advanced technologies and approaches in drug development is a natural fallout from the new precidence in medicine, and it heralds a new epoch in the battle against cancer.

- **Innovations in Biomarker Identification**

Biomarkers are important in precision oncology as indicators of disease development or progression, and predictors of the outcomes of treatment. Advances in biomarker detection have, over the years, made it easier to understand how therapy may need to be tailored for each patient. Liquid biopsies enable complete examination of tumor genetic material, while next-generation sequencing allows for detection of circulating tumor DNA [8]. With these techniques, certain mutations may then be discovered and identified and consequently may

guide therapy choices. For example, the discovery that the HER2/neu gene was amplified in patients with breast cancer formed the basis upon which targeted medicines such as trastuzumab came to be and have been known to greatly change patient outcomes. It will be part of the ongoing quest for new biomarkers contributing to better treatment effectiveness in terms of ability to identify cancer early and classification of the patient to target the therapy.

- **Role of Genomics and Proteomics**

The basics of genomics and proteomics are the roots on which drug discovery in cancer is founded. The term genomics is used to refer to the study of the total DNA of an organism, that is, its genes and their activities [9]. Important recent understanding and knowledge about genetic variants leading to causation of susceptibility to and development of cancer has been gathered by the Human Genome Project and thus has helped significantly in this profession. By studying the patterns of alterations that characterise tumor, scientists can discover those that have been targeted for therapeutic intervention and which might have practical application in reality. For example, mutations identified in the BRAF gene have led to the development of targeted inhibitors specific to melanoma patients.

Conversely, proteomics is a large-scale study on the massive structure of proteins, particularly on their structures and activities. Provided that the proteome, or the total set of proteins produced in a cell, is understood clearly, researchers may be able to find certain treatment targets and clarify the signaling pathways involved with the development of cancer [10]. The new view of tumor-specific antigens has, significantly aided by the advances of mass spectrometry and bioinformatics techniques, opened doors for new immunotherapies. Integration between genomes and proteomics could further drive towards an integrative understanding of cancer biology, with subsequent development of tailored treatments, peculiarities unique to a particular patient's tumor.

- **High-Throughput Screening Techniques**

High-throughput screening or HTS methods have changed the drug development process to revolutionize rapid assessments of hundreds of chemicals' possible anti-cancer action. Thousands of drug candidates can be tested against specific biological targets at one time due to automation and downsizing studies which speed up the pace of discovery. HTS is very useful in discovering tiny compounds that can either activate or inhibit key pathways associated with cancer [11]

Being the case, HTS presents a multiplicity of assay formats that include biochemical, reporter, and cell-based assays offering flexible platforms used to assess drug toxicity and effectiveness. The fact that the cell lines could be produced from various cancer types allows one to evaluate the efficacy of chemicals across the range of malignancies. But advances in artificial intelligence and data analytics also improve the interpretation of screening results, which thereby informs promising individuals for future growth. With this prediction of how HTS would interact with biological targets, computational modeling in concert with HTS helps to generate more potent medicinal compounds. By considering everything, HTS has transformed the process of drug development such that now this process is more efficient and the probability of fast-finding targeted treatments is eased which may combat against the complex nature of cancer.

2. THE PM PROCESS AND INTEGRATION INTO CANCER TREATMENT

The objective of the discipline of PM is to provide an individualized treatment for an individual or a group of individuals using information about his or her state of physical condition, history, and exposure to the environment. Such facts split up the patients into groups for various clinically relevant reasons. For instance, it can be used in PM to identify patient groups for clinical trials, the genetic susceptibility of a person toward a particular disease, and who should benefit most from treatment.

With the Human Genome Project (HGP) having been completed, scientists can now read and interpret a person's genetic code and identify genetic susceptibilities to certain diseases. This monumental event has aptly transformed the perspective on health from one of reaction to prevention [12]. Scientists are now trying to describe how genetic predispositions are impacted by environmental exposures and to attain an all-round view of how the body functions at different omics levels [13]. And once this all gets mixed, it will eventually help the doctors as well as the scientists to make more accurate predictions about patient reactions to specific treatments. Patients who are undergoing CDx assay are evaluated for specific genetic characteristics, which will determine a response to a specific treatment. These tests prove to be useful instruments that support tailored medicines. Treatment could be significantly affected by this strategy for the patient. The revolutionary shift is from a doctor choosing a generic medication that is essentially experimental for the patient to one that uses PM to successfully target the illness [14].

This review talks about precision medicine, or PM, along with personalized medicine. The field was first termed as personalized medicine, although nowadays the names are often interchangeable since they both refer to the application of a patient's unique traits to select the best course of treatment [15]. But as it was used more and more often in society and the media and even in science, the meaning was also lost [16]. People tended to use the term, meaning that since the treatment was "personalized," it was made for an individual. In fact, the term was coined by the scientific community, more specifically the National Research Council which instead of the misleading phrase personalized medicine termed it as precision medicine21, in order to adequately emphasize the actual nature of the topic [17]. However, the awareness among the general public of tailored medicine remains on an increasing trend. Here, in this study, we have considered both the terminologies as include many points of views that emerge in the last few years and to recognize development of the language.

Three categories—which are highlighted by the flowchart in Fig. 2—characterize the current status of the field of PM with regard to cancer in this research [18]. We begin by summarizing the protocols for (1) Obtaining PM Data. This paper reviews the various omics techniques (genomics, transcriptomics, proteomics, and metabolomics) used to delineate a patient's disease state. (2) Shaping a PM Therapy covers the interpretation and use of these data as instruments in treatment choice and clinical study design. Emerging cancer products, including organoids, mAbs, cancer vaccines, and CAR T-cells, are also provided from a PM perspective [19]. To ensure that PM products are safe and efficacious, the ever-changing federal laws are also addressed. The ethical and economic implications of PM are addressed in (3) Broader Implications of PM. Economic considerations-making an institution of PM challenging and may require altering the current insurance-payer system-are also involved. Ethical concern: The nature of the industry might be daunting because it does involve creating adequate protections for the medical and personal information of identified patients [20].



Figure 1: PM (Personalized Medicine) Market and Share

3. RESEARCH METHODOLOGY

3.1.Research Design

This research explored various cancer types, reactions to targeted therapies, adverse events, and health insurance coverage for treatments using a descriptive cross-sectional method. Objectives involved the calculation of incidences of various cancer types, assessment of patient responses to treatment, evaluation of how health insurance coverage may impact the access to care, and assessment of side effects during the course of the treatment.

3.2.Study Population

The study population represents cancer patients with targeted treatments for the different types. A sample size of 200 patients was selected to ascertain an adequately strong representation of the patient population, as evidenced in the data tables presented.

3.3.Sampling Method

Purposive or convenience sampling-the technique of sampling without probability-allowed participants to be chosen from cancer clinics or hospitals. They were patients on targeted therapy who corresponded to more than one age group, gender, and phase of cancer. This approach allowed a close examination of a particular population affected by cancer.

3.4.Data Collection

The data was established from surveys that introduced extended information on the nature of the cancer, demographics of the patient, treatment with targeted therapies being full, partial, stable, and progressive, reactions to the treatment, adverse events such as fever, tiredness, nausea, hair loss, among other symptoms, and lastly how much the insurance covered the therapies fully, partially, or not at all. The data was gathered through the use of these surveys, which were in a position to reach patients either by way of interviews or in forms which the patients can fill up in any therapeutic environment. Informed permission was first sought from each participant and then collected the ethical clearance before collecting data from them.

4. DATA ANALYSIS

The distribution of types of cancer in a sample of patients is listed in Table 1, which also showed the prevalence of different cancers that exist in this group. Since 20% of patients have lung cancer, it is the most common form of cancer, and it seems that respiratory cancers are a growing threat to public health. After lung cancer, the second-most common malignancy is breast cancer, accounting for 17.5% of cases. This also leads to a call for further screening and research in the field of women's health.

Table 1: Distribution of Cancer Types Among Patients

Cancer Type	Frequency	Percentage (%)
Lung Cancer	40	20
Breast Cancer	35	17.5
Colorectal Cancer	30	15
Prostate Cancer	25	12.5
Ovarian Cancer	20	10
Other	50	25
Total	**200**	**100**



Figure 2: Graphical representation on the percentage of Cancer Types among patient

Considering prostate cancer affects 12.5% of patients, and colorectal cancer afflicts 15% of the population, it is evident that there needs to be targeted education and preventive interventions mainly targeted to older populations. 10% of patients suffer from ovarian cancer, another condition which needs to be emphasized due to the mortality rate and often late detection. Finally, 25% of this sample falls into the category "Other," or, put another way, there is a gamut of different cancers that are more common in this group. Overall, the data demonstrates the variability in cancer prevalence, thus aligning research and health care priorities with more efficient methods of detection, treatment, and prevention tailored to the unique needs of different patient populations.

Table 2: Response to Targeted Therapies

Response	Frequency	Percentage (%)
Complete Response	30	15
Partial Response	60	30
Stable Disease	70	35
Progressive Disease	40	20
Total	**200**	**100**



Figure 3: Graphical Representation on the percentage of Targeted Therapies

Results of the patients to the targeted therapy appear in Table 2, which gives very important information concerning how effectively these treatments work. There was a full response in 15% of the 200 patients evaluated; that is to say, their cancers have substantially shrunk or even disappeared. This evidences targeted medicines with substantial therapeutic benefits. A higher percentage, 30% had partial response, wherein their cancer is not completely cured but can so be identified that there was a noticeable retardation of cancerous growth or size; this somewhat proves the efficacy of the treatments to the cancers involved. In addition, 35% of the patients had a stable illness in which there was no reappearance or progress of their cancer. This still translates to a good outcome for most patients as care can be continued, and quality of life can be increased. However, 20% of patients had progressive disease, meaning even with therapy, their cancer was continuing to grow which raises many questions regarding how well these drugs work in this population. The data as a whole shows the varied response to target therapy, and customized treatment plans should be designed to better reflect the distinct patient-specific features that will bring about better results and improvements in cancer care.

Table 3: Adverse Events Reported in Clinical Trials

Adverse Event	Frequency	Percentage (%)
Nausea	50	25
Fatigue	40	20
Hair Loss	30	15
Fever	25	12.5
Other	55	27.5
Total	**200**	**100**



Figure 4: Graphical Representation on the percentage of Adverse Event

The adverse events associated with clinical use of targeted therapeutics are summarized in Table 3 and are crucial to understanding possible side effects that the patient may experience during therapy. Of the 200 patients, nausea was the most commonly experienced adverse event, affecting 25% of patients. This indicates the importance of adequate antiemetic care in ensuring patient comfort and thereby therapeutic compliance. Fatigue was the most common adverse effect, affecting 20% of patients. This is a significant concern since it could indicate that many patients experience low levels of energy during therapy, which in turn may negatively impact their quality of life. While hair loss, affecting 15% of participants, is a well-documented side effect of many cancer therapies, it can have psychological implications for those who experience it. 12.5% of patients presented with fever, which may represent underlying diseases or immunological responses in response to the treatments. Additionally, the "Other" category represents many adverse events that were unspecified and were found in 27.5% of patients. This shows the variety of side effects that could arise and the need for vigilant monitoring and reporting. From this, the information is therefore critical in making it clear that the management of adverse events and the effectiveness of treatment will always go hand in hand. It is through this that healthcare practitioners can better accompany patients on their therapy journey and thereby enhance their overall treatment experience.

Table 4: Insurance Coverage for Targeted Therapies

Coverage Status	Frequency	Percentage (%)

Fully Covered	100	50
Partially Covered	80	40
Not Covered	20	10
Total	**200**	**100**



Figure 5: Graphical Representation on the percentage of Coverage Status

Table 4: Number of 200 patients with health coverage for targeted therapies. It is highly indicative in terms of access to treatment because 50% of the patients reported that their insurance fully covers their targeted therapies. That's promising because it indicates that a significant section of the patient population can get these important treatments without having to pay out-of-pocket for it. Further, 40% of the patients opined that they suffered from a lack of coverage. In the event that some of the expenses are recovered, there is a possibility that the patient may end up paying out-of-pocket costs that may, in turn, limit their access to full treatment. However, 10% of the patients reported that they had incurred no costs regarding their targeted therapies. There becomes a query regarding the fair access this group can have to life-saving medicines. This lack of coverage would discourage patients from seeking recommended therapy, thereby affecting their health outcomes. What the report points out is the significance of insurance policies to query the availability of targeted drugs. The report also indicates the necessity of persistent lobbying aimed at making coverage and cost barriers decrease for all the patients in need of these critical drugs.

5. CONCLUSION

This study also shows that the revolution of cancer can be done through precision medicine and targeted medicines, which focus on better patient outcomes through tailor-made treatment plans. Incidences of various types of cancers with differences in response to treatment and an essential role played by insurance coverage in the delivery of these treatments call for tailored treatments according to genetic, environmental, and demographic variables. The results bring out promising efficacy of targeted treatments, as seen in the meaningful percentage of full and partial responses; however, side events and insurance discrepancies must be addressed to maximize patient care. In the final analysis, the aim of improving precision medicine in oncology is to establish fair access to cutting-edge therapies simultaneously enhancing therapeutic effectiveness and improving health outcomes in patients with cancer.

REFERENCES

1. *Bashraheel, S. S., Domling, A., & Goda, S. K. (2020). Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedicine & Pharmacotherapy, 125, 110009.*
2. *Dugger, S. A., Platt, A., & Goldstein, D. B. (2018). Drug development in the era of precision medicine. Nature reviews Drug discovery, 17(3), 183-196.*
3. *Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. Genome medicine, 14(1), 101.*
4. *Gu, W., Meng, F., Haag, R., & Zhong, Z. (2021). Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Journal of controlled release, 329, 676-695.*
5. *Hartl, D., de Luca, V., Kostikova, A., Laramie, J., Kennedy, S., Ferrero, E., ... & Roth, A. (2021). Translational precision medicine: an industry perspective. Journal of translational medicine, 19(1), 245.*
6. *Heymach, J., Krilov, L., Alberg, A., Baxter, N., Chang, S. M., Corcoran, R. B., ... & Burstein, H. (2018). Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology, 36(10), 1020-1044.*
7. *Ho, D., Quake, S. R., McCabe, E. R., Chng, W. J., Chow, E. K., Ding, X., ... & Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. Trends in biotechnology, 38(5), 497-518.*
8. *Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., ... & Yarmush, M. L. (2018). The growing role of precision and personalized medicine for cancer treatment. Technology, 6(03n04), 79-100.*
9. *Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018). Molecular therapies and precision medicine for hepatocellular carcinoma. Nature reviews Clinical oncology, 15(10), 599-616.*
10. *Luo, X. Y., Wu, K. M., & He, X. X. (2021). Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental & Clinical Cancer Research, 40(1), 172.*
11. *Malone, E. R., Oliva, M., Sabatini, P. J., Stockley, T. L., & Siu, L. L. (2020). Molecular profiling for precision cancer therapies. Genome medicine, 12, 1-19.*
12. *Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., ... & Voest, E. (2022). Delivering precision oncology to patients with cancer. Nature medicine, 28(4), 658-665.*
13. *Morash, M., Mitchell, H., Beltran, H., Elemento, O., & Pathak, J. (2018). The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. Journal of personalized medicine, 8(3), 30.*
14. *Morganti, S., Tarantino, P., Ferraro, E., D'Amico, P., Duso, B. A., & Curigliano, G. (2019). Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational research and onco-omics applications in the era of cancer personal genomics, 9-30.*
15. *Pinto, C., Biffoni, M., Popoli, P., Marchetti, A., Marchetti, P., Martini, N., & Normanno, N. (2021). Molecular tests and target therapies in oncology:*

Recommendations from the Italian workshop. Future oncology (London, England), 17(26), 3529-3539.

16. *Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020). Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer treatment reviews, 86, 102019.*
17. *Yan, L., & Zhang, W. (2018). Precision medicine becomes reality—tumor type-agnostic therapy. Cancer Communications, 38(1), 6.*
18. *Yang, S. R., Schultheis, A. M., Yu, H., Mandelker, D., Ladanyi, M., & Büttner, R. (2022, September). Precision medicine in non-small cell lung cancer: Current applications and future directions. In Seminars in cancer biology (Vol. 84, pp. 184-198). Academic Press.*
19. *Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z. S., Kumar, A., ... & Tang, H. (2023). Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular cancer, 22(1), 105.*
20. *Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018). Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precision clinical medicine, 1(1), 29-48.*

*****